research BH15 Efficacy and safety of baricitinib in the management of severe alopecia areata over a 6-month period: a real-world experience
Baricitinib was effective and safe for severe hair loss treatment over 6 months.
Search
for
Sort by
Research
510-540 / 1000+ results 
research Severe and Fatal Phenobarbitone Eruptions
Phenobarbitone can cause severe and sometimes fatal skin reactions.
research Combination of baricitinib and conventional immunomodulating therapy for alopecia totalis
Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
research Review of Baricitinib in the Treatment of Alopecia Areata.
Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
research A randomized, double‐blind, controlled trial of testosterone gel treatment versus vehicle control on the facial hair of young men with beta‐thalassemia major
Testosterone gel helps increase facial hair in young men with beta-thalassemia major.
research Temporal Triangular Alopecia: Report of Five Cases in Asian Children
Temporal triangular alopecia is a non-scarring hair loss seen in some Asian children.
research Defining a Therapeutic Window of Opportunity in Alopecia Areata: Predictors of Early Response to Baricitinib
Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.
research Alopecia Areata Barbae in a Nutshell
Beard alopecia areata causes patchy beard hair loss, often treatable with janus kinase inhibitors.
research Trajectories For Scalp Hair Regrowth In Patients With Severe Alopecia Areata Treated With Baricitinib
Baricitinib helps patients with severe alopecia areata regrow hair.
research 43696 Early real-world experience with baricitinib in the treatment of severe alopecia areata
Baricitinib shows promise in treating severe hair loss.
research Temporal Triangular Alopecia – A Diagnostic Dilemma: Case Series of Six Patients
Trichoscopy effectively diagnoses temporal triangular alopecia in children.
research Real-life Data for Tenofovir Alafenamide Fumarate Treatment of Hepatitis B: the Pythagoras Cohort
Tenofovir alafenamide fumarate is effective and safer for hepatitis B, with fewer side effects than tenofovir disoproxil fumarate.
research Tuberous sclerosis: Clinical findings in 57 patients
Most patients with Tuberous sclerosis had neurological or skin issues, and over half had psychiatric problems.
research Two novel BTD mutations causing profound biotinidase deficiency in a Chinese patient
The study found two new mutations in a Chinese patient with severe biotinidase deficiency.
research Beard hair response in Alopecia Areata Universalis treated with baricitinib
Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.
research Body Focused Repetitive Behavior at an Unusual Site and in an Unusual Pattern - Symmetrical Trichotillomania
Trichotillomania can occur in unusual patterns and sites, highlighting the need for awareness and treatment options.
research Chronic toxicity of 3,4,3′,4′-tetrachlorobiphenyl in the marmoset monkey (Callithrix jacchus)
High doses of TCB cause severe health issues in marmoset monkeys.
research Real‐life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24‐week Italian study
Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.
research Trichoscopy: A Useful Tool in Diagnosing Temporal Triangular Alopecia
Trichoscopy effectively diagnoses temporal triangular alopecia in children.
research Baricitinib in Alopecia Areata: Real-Life Changes in Lipid Profile and Hematologic Inflammation Indices at 52 weeks
Baricitinib effectively treated alopecia areata in 73% of patients, with minor metabolic changes and significant changes in inflammatory markers.
research Recurrent MBTPS2 variant c.970+5G>A in IFAP syndrome: a mutational hotspot
The MBTPS2 gene variant c.970+5G>A is a common mutation causing IFAP syndrome.
research Possible Involvement of Skin‐Resident Memory T Cells in Refractory Chronic Alopecia Areata
Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.
research MP-09.08
The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.
research Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
research Real‐life effectiveness and safety of baricitinib in adults with alopecia areata: A multicentre study
Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.
research Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
research Evaluation of efficacy, safety, and reversibility of combination regimen of cyproterone acetate and testosterone buciclate in bonnet monkey
The right dosage of CPA and TB can work as a safe and reversible male contraceptive in monkeys.
research Visualizing Severity of Alopecia Tool (SALT) scores in the clinical setting using patient images from a clinical trial
The study helps doctors use patient images to understand and apply SALT scores for treating severe alopecia areata.
research Characterizing Loss of Response Occurring in a Small Number of Patients During 3 Years of Long-Term Maintenance Therapy with Baricitinib 4-mg: Results From BRAVE-AA1 and -AA2 Trials
Some patients on Baricitinib for alopecia areata lost response, often linked to longer and more severe initial conditions.
research Baricitinib in the Management of Severe Alopecia Areata: A Report of Two Cases With Sustained Clinical Response
Baricitinib effectively regrows hair in severe alopecia areata cases.